ZIM Laboratories Limited has published newspaper advertisements announcing its Extraordinary General Meeting (EGM) scheduled for February 16, 2026, in compliance with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

EGM Details and Publication

The pharmaceutical company submitted newspaper publication copies to BSE Limited and National Stock Exchange of India Limited on January 22, 2026. The advertisements were published in three newspapers to ensure wide coverage across different linguistic communities.

Newspaper Coverage

The EGM notice was published in the following newspapers to comply with regulatory disclosure requirements:

• The Financial Express (English) - All India Edition
• Indian Express (English) - Nagpur Edition
• Lokatta (Marathi) - Local newspaper

This multi-language publication strategy ensures comprehensive reach to shareholders across different regions and language preferences.

Regulatory Compliance

The company's submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was digitally signed by Piyush Siddheshwar Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), demonstrating proper authorization and compliance protocols.

Meeting Accessibility

Shareholders will have multiple ways to access meeting information and participate in the proceedings. The EGM notice will be distributed through email to registered shareholders and made available on various digital platforms including the company's website and stock exchange portals.

The company has emphasized that the meeting will follow all applicable circulars issued by the Ministry of Corporate Affairs (MCA) and SEBI regarding virtual meetings and e-voting procedures. This approach aligns with current corporate governance practices that prioritize shareholder accessibility while maintaining regulatory compliance.

Zim laboratories Limited has announced a major corporate development with its board of directors approving a comprehensive share issuance plan. The pharmaceutical company's board has given the green light to issue up to 47,64,497 shares at a fixed price of ₹73.46 per share to Florintree Trinex LLP.

Share Issuance Details

The proposed share issuance represents a significant capital raising exercise for the company. The key parameters of this transaction are outlined below:

Shareholder Approval Process

While the board has approved the share issuance plan, the company must obtain formal shareholder consent before proceeding with the transaction. Zim Laboratories has scheduled a special meeting specifically to address this proposal and secure the necessary approvals from its shareholders.

Corporate Governance Framework

The structured approach adopted by Zim Laboratories demonstrates adherence to proper corporate governance practices. The company is following the established protocol of obtaining board approval first, followed by seeking shareholder consent through a dedicated special meeting. This two-tier approval process ensures transparency and proper oversight of significant corporate transactions.

The substantial nature of this share issuance, involving nearly 48 lakh shares, underscores the importance of obtaining explicit shareholder approval before implementation. The company has provided shareholders with adequate notice by scheduling the meeting well in advance, allowing sufficient time for review and consideration of the proposal.